Related Experiment Video

Updated: Jan 9, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

Ibrutinib Inhibits Tumor Progression, Alleviates Pain, and Protects the Tibia in a Bone Metastasis Model of Lung

Rong-Guang Luo1, Xian-Bing Xie2, Yuan-Yuan Zhang3

  • 1Department of Medical Imaging and Interventional Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P.R. China.

Anticancer Research
|November 29, 2025
PubMed
Abstract

Insights

Ibrutinib effectively inhibits lung cancer cell growth and migration. In bone metastasis models, it reduces pain, preserves bone density, and decreases tumor burden, offering a potential dual-action therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metastasis Research

Background:

  • Lung cancer bone metastasis severely impacts patient quality of life, causing pain and fractures.
  • Current treatments lack the ability to simultaneously inhibit metastatic growth and alleviate pain.
  • Ibrutinib, an EGFR inhibitor, shows promise in inhibiting lung cancer cell proliferation and migration.

Purpose of the Study:

  • To investigate the effects of ibrutinib on lung cancer progression, pain management, and bone protection in a bone metastasis model.
  • To assess ibrutinib's impact on cancer cell viability and migration in vitro.
  • To evaluate ibrutinib's efficacy in reducing pain and preserving bone integrity in vivo.

Main Methods:

  • In vitro: CCK-8, wound healing, and transwell assays assessed lung cancer cell viability and migration after ibrutinib treatment.
  • In vivo: Tumor-bearing mice underwent behavioral tests, micro-computed tomography, and histological analysis to evaluate pain, bone status, and metastasis.
  • Specific assays included mechanical allodynia, flinches, pain scoring, TRAP staining, and TUNEL staining.

Main Results:

  • Ibrutinib significantly suppressed lung cancer cell proliferation and migration in vitro.
  • In vivo, ibrutinib treatment reduced mechanical and spontaneous pain, delayed motor function loss, and increased bone volume and density.
  • Histological analysis showed decreased lung metastatic lesions, reduced osteoclast numbers, and increased tumor cell apoptosis.

Conclusions:

  • Ibrutinib demonstrates efficacy in inhibiting lung cancer cell proliferation and migration.
  • The drug effectively inhibits tumor growth, alleviates pain, and protects bone in a lung cancer bone metastasis model.
  • Ibrutinib presents a potential therapeutic strategy for managing lung cancer bone metastasis, addressing both tumor progression and pain.
Keywords:
Lung cancerbone metastasisbone protectionibrutinibpain

More Related Videos

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone06:53

Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone

Published on: September 9, 2020

3.2K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K